Headline
Novavax is uniquely qualified to address the enduring need for innovative vaccines
Who is Novavax?
We are a late-stage biotechnology company that promotes improved global health through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.
We have more than a decade of experience contending with some of the world’s most devastating diseases, including COVID-19, seasonal influenza, RSV, Ebola, MERS, and SARS. Hard-won lessons and significant advances illustrate that our proven technology has tremendous potential to make a substantial contribution to public health worldwide.
Our vaccine candidates are genetically engineered using three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis.
We are also developing proprietary immune-stimulating saponin-based adjuvants at Novavax AB, our wholly owned Swedish subsidiary. Matrix-M™ has been shown to enhance immune responses and has been well tolerated in multiple clinical trials.
Dr. Nita Patel, Kelsey Jacobson, Dr. Rhonda Flores, and Dr. Sonia Maciejewski are on the research team working on the genetic sequencing for vaccine candidate development.
Our Team
Our team is composed of experts in drug development who understand science, technology, medicine, and their global context. Our deeply experienced team is unified in the quest to reduce the burden of infectious disease around the globe.
Meet the leaders who work relentlessly to address urgent global health needs.
Chief Executive Officer
Mr. Erck was named president and chief executive officer of Novavax in April 2011. He became a Novavax director in June 2009 and served as its executive chairman of the board beginning in February 2010. From 2000 to 2008, Mr. Erck was president and chief executive officer of IOMAI Corporation, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate. Mr. Erck previously served as president and chief executive officer at Procept, a publicly traded immunology company, as vice president of corporate development at Integrated Genetics (now Genzyme), and in management positions within Baxter International. Mr. Erck currently sits on the board of directors of MaxCyte, Inc. He received an undergraduate degree from the University of Illinois and a master’s degree in business administration from the University of Chicago Booth School of Business.
Research and Development
Dr. Glenn is the president of research and development and leads the discovery, clinical, and regulatory teams. He has spent 28 years in the design and development of vaccines, vaccine delivery, and adjuvants. He has led the development of products from concept to late-stage clinical development, including COVID-19, RSV, recombinant adjuvanted seasonal and pandemic influenza vaccines, Ebola, and an Enterotoxigenic E. coli vaccine patch, and participated in other programs including the development of a malaria vaccine. He is the cofounder of IOMAI and provided the scientific and technical leadership that led to the acquisition by Intercell in 2008. He worked for Intercell from 2008 to 2010. He is the coauthor of more than 100 peer-reviewed scientific publications. Dr. Glenn was board certified and practiced pediatrics prior to completing a Medical Research Fellowship at the Walter Reed Army Institute of Research where he continued as a clinician-researcher prior to entering into commercial vaccine development in 1997. Dr. Glenn received a bachelor of arts degree in biology and chemistry from Whitman College in Washington and a doctor of medicine degree from Oral Roberts University School of Medicine in Oklahoma.
Chief Financial Officer
Mr. Covino joined Novavax in November 2020 as executive vice president and chief financial officer with responsibility for financial strategy, performance and reporting and corporate funding. Prior to joining Novavax, Mr. Covino was group chief financial officer at GlaxoSmithKline’s TESARO Oncology Division, where he also served as senior vice president and chief accounting officer. He previously served as chief accounting officer at Biogen Inc. as well as vice president, corporate internal audit and control and vice president, international finance for Boston Scientific. Earlier in his career, Mr. Covino spent 10 years at international accounting and consulting firm PricewaterhouseCoopers. He holds a Bachelor of Science in Business Administration from Bryant University.
Chief Medical Officer
Dr. Dubovsky is executive vice president, chief medical officer with responsibility for medical and clinical affairs and related activities at Novavax. A recognized leader in vaccine development, Dr. Dubovsky brings more than 20 years of infectious disease experience to Novavax. He joined Novavax from AstraZeneca, where he was head of clinical engagement and policy and deputy chief medical officer for clinical affairs. Before that, he oversaw the clinical development of early and late-stage infectious disease and vaccine assets at MedImmune, which was subsequently acquired by AstraZeneca. Previously, he created and managed a portfolio of 25 malaria vaccine candidates spanning early candidate optimization to Phase 3 clinical studies at PATH’s Malaria Vaccine Initiative. He is the coauthor of more than 50 peer-reviewed scientific publications and currently sits on the board of directors of the Sabin Institute. Dr. Dubovsky earned his master of public health degree from Johns Hopkins University and his doctor of medicine degree from the University of Alabama. He completed his pediatric training at Stanford University, his pediatric infectious disease fellowship at the Center for Vaccine Development at the University of Maryland, and his preventive medicine training at Johns Hopkins University.
Chief Legal Officer and
Corporate Secretary
Mr. Herrmann joined Novavax in 2010 and is responsible for managing all of its legal affairs, including its patent portfolio, transactional and contractual matters, and public securities filings, and oversight of corporate and business development activities, along with attending to all the duties of corporate secretary. Mr. Herrmann also works with the senior management team at Novavax to define and develop corporate policies and procedures. Prior to joining Novavax, Mr. Herrmann was general counsel at Ore Pharmaceuticals and deputy general counsel at Gene Logic before it became Ore Pharmaceuticals. Mr. Herrmann previously worked as senior counsel for Celera Genomics and as senior corporate counsel at Baxter Healthcare in its renal division. Mr. Herrmann received a bachelor of arts degree in political science and history from Brown University and a juris doctorate from the University of Illinois.
Chief Human Resources Officer
Ms. Hoyt is executive vice president of human resources with full responsibility for the company’s human resources duties and activities including talent acquisition, retention and development as well as rewards and benefits. Her significant expertise and experiences were pivotal in the development and expansion of the company’s employee base in both the United States and Sweden. Ms. Hoyt has implemented leadership strategies for the development of comprehensive human resources programs in support of the company’s strategic plans, while also driving cultural development (a quality for which Novavax has been recognized several times, including placement on the Washington Post’s Top Workplaces). Prior to joining Novavax in 2008 as vice president of human resources, Ms. Hoyt held positions of increasing responsibility at several organizations, including ChoicePoint, 3e Technologies International, Inc., and TRW. Ms. Hoyt received a bachelor of science degree in business administration from Shepherd University and a master of science degree in human resource management from Marymount University.
CMC
Mr. Machielse brings more than 25 years of biotechnology industry experience to Novavax. He was most recently chief executive officer of rare disease company Vtesse, before its acquisition by Sucampo Pharmaceuticals, Inc., now a part of Mallinckrodt. Previously, he was chief operating officer at Omthera Pharmaceuticals, where he oversaw development and approval of a treatment for hypertriglyceridemia and was integral to the company’s IPO and acquisition by AstraZeneca. Earlier, as executive vice president of operations for MedImmune, later acquired by AstraZeneca, he led worldwide development and operations of the company’s therapeutic antibodies, small molecules and vaccine products. Additionally, he was responsible for development of MedImmune’s H1N1 influenza vaccine, which was the first to be approved by FDA. He currently sits on the board of directors of Comet Therapeutics, Complexa Therapeutics and Polyneuron. Mr. Machielse received a bachelor of science degree in medical biology and a master of science degree in biochemistry from the University of Utrecht in the Netherlands.
Chief Commercial Officer and
Chief Business Officer
Mr. Trizzino is executive vice president, chief business officer and chief commercial officer with responsibility for global commercial strategy and execution and oversight of IT, investor and public relations, and corporate affairs. He has broad experience in publicly held companies and in vaccines, with previous roles overseeing commercialization, policy, strategy, business development, financing, and investor and public relations. Since rejoining Novavax in 2014, he has held roles of increasing responsibility, including chief financial officer and senior vice president of commercial operations. Mr. Trizzino served as CEO of Immunovaccine in 2011, successfully leading the company into clinical development while securing the funding commitments required to advance the company’s lead candidate. Earlier in his career, Mr. Trizzino held leadership roles at several companies with a focus in infectious disease vaccine markets, including MedImmune, LLC (now AstraZeneca), ID Biomedical and Henry Schein, Inc. Mr. Trizzino holds a bachelor of science degree from Long Island University, CW Post and a master of business administration degree from New York University, Stern School of Business.
NanoFlu General Manager
Mr. Wilson is executive vice president and NanoFlu general manager with responsibility for leading the efforts to advance NanoFlu through global licensure. Mr. Wilson joined Novavax in 2011 as senior vice president, business development, and most recently was responsible for global business development, quality, and program management functions across the company’s entire pipeline. Prior to joining Novavax in November 2011, Mr. Wilson was most recently the chief financial officer at Supernus Pharmaceuticals. He was previously senior vice president, chief financial officer, and general counsel of Iomai Corporation, which was acquired in 2008 by Intercell AG, during which time he successfully negotiated a $128 million government contract with the Office of Biomedical Research and Development Authority (BARDA) at the US Department of Health and Human Services. Mr. Wilson was also the acting general counsel of North American Vaccine, Inc. until its acquisition by Baxter International in 2000. Mr. Wilson received a bachelor of arts degree in history from Princeton University and a master degree in business administration and a juris doctorate from the University of Virginia.
Corporate Development
Mr. Andréasson is senior vice president of corporate development with responsibility for identifying, prioritizing, and evaluating new strategic opportunities for Novavax that leverage core strengths and accelerate growth initiatives. Mr. Andréasson joined Novavax in June 2014 with many years of experience in biopharmaceutical operations, executive management, and strategic development. From 2012 to 2013, he served as the chief executive officer of Isconova AB in Uppsala, Sweden, a leading international vaccine adjuvant company acquired by Novavax in 2013 and currently operating as Novavax AB. Prior to his role at Isconova AB, Mr. Andréasson served as the chief executive officer of Beta-Cell NV in Brussels, Belgium from 2008 to 2012 and as chief executive officer of Active Biotech AB in Lund, Sweden from 1999 to 2008. Mr. Andréasson spent a number of years in roles inside Pharmacia Corporation, including president of Pharmacia SA, France, president of KabiPharmacia International, and president of Pharmacia Arzneimittel GmbH, Germany. Mr. Andréasson received a bachelor of science degree in business administration and economics from the Stockholm School of Economics in Sweden.
Sales
Mr. Czworka is senior vice president of sales with responsibility for global customer engagement activities. He brings more than two decades of biopharmaceutical experience to Novavax, most recently serving as vice president, global customer engagement at U.S. Pharmacopeia. In sales and marketing leadership positions at Osiris Therapeutics, Auxilium Pharmaceuticals, MedImmune and TAP Pharmaceuticals, Mr. Czworka has assembled, developed, deployed and directed award-winning global sales and marketing teams to achieve business objectives. He has launched multiple medications across a variety of therapeutic areas while increasing patient access to vital treatments. Mr. Czworka received a bachelor of science degree in business administration – marketing from the University of Central Florida.
CMC, NanoFlu
Dr. Hahn is senior vice president of CMC for NanoFlu with responsibility for leading all CMC activities for the NanoFlu program. Dr. Hahn has 28 years of commercial vaccine and antibody manufacturing experience and a proven track record with clinical and commercial products, process innovation, technology transfer, facility start-up, GMP compliance, and regulatory inspections. Dr. Hahn joined Novavax in June 2011 as senior vice president of manufacturing and process development and was later named senior vice president of global manufacturing operations with responsibility for production sites in the United States and Europe. Prior to joining Novavax, he was vice president of antibody manufacturing and later vice president of vaccine manufacturing at MedImmune, LLC, with responsibilities for sites in the United States and Europe. Prior to MedImmune, he spent more than 15 years in vaccine manufacturing with Merck & Co. Dr. Hahn received a bachelor of science degree in chemical engineering from Lehigh University and a master of science and a doctorate degree in chemical engineering from Stanford University.
Chief Information Officer
Mr. Lee is senior vice president and chief information officer with responsibility for leading the information technology operations, network infrastructure, enterprise applications, project management, and cybersecurity programs. He works closely with senior management to align IT investments with corporate strategy and business objectives. He joined Novavax in 2017 as senior director of IT with more than 20 years of IT experience, the vast majority of which has been in the life sciences industry. Prior to joining Novavax, he served as vice president of cloud solutions at IPDS, Inc., an information technology services company, where he led development and implementation of the cloud solutions portfolio. Mr. Lee previously held positions of increasing responsibility at Human Genome Sciences (HGS) leading up to its acquisition by GlaxoSmithKline (GSK). He led the global IT integration and successfully completed the disposition of all IT assets during the transition of HGS into GSK.
Commercial Strategy
Mr. Rosen is senior vice president of commercial strategy with responsibility for leading commercial strategy efforts instrumental to ensuring future patient access to Novavax vaccines. Mr. Rosen joined Novavax in 2015 as vice president of market access and policy and was named vice president of commercial strategy in June 2018. He came to Novavax with more than 20 years of industry, legal, and patient advocacy experience with the vast majority engaged in government affairs, advocacy, reimbursement, and policy work. Prior to Novavax, Mr. Rosen was most recently the chief policy, advocacy and patient access officer for the Leukemia & Lymphoma Society, where he oversaw all legislative and regulatory efforts and the delivery of patient services nationwide; prior to that, he developed and ran the government affairs, policy, and alliance development functions for MedImmune. Mr. Rosen currently serves as chair of the board of directors of Learning Undefeated, a nonprofit that provides STEM education and workforce development to underserved communities. Mr. Rosen received a bachelor of arts degree in history and psychology from Tufts University and a juris doctorate from Hofstra University School of Law.
Investor Relations and
Corporate Affairs
Ms. Taylor is senior vice president, investor relations and corporate affairs with responsibility for investor relations, public relations, and corporate communications activities at Novavax. She brings more than 25 years of communications and commercial leadership to Novavax. Most recently, she was vice president of global corporate affairs and communications at Autolus Therapeutics plc, where she led all financial, scientific, and corporate communications. Prior to Autolus, Ms. Taylor was senior vice president of global investor relations and corporate affairs at Sucampo. Earlier in her career, she held positions of increasing responsibility at MedImmune LLC, the global biologics arm of AstraZeneca, including head of marketing responsible for the commercialization of the company’s respiratory syncytial virus and influenza franchises, as well as roles at Pfizer, where she served in key brand and consumer marketing roles. She has also worked in public relations and communications roles in agency and nonprofit settings. Ms. Taylor earned a master of business administration degree from Columbia University and a bachelor of arts degree in foreign affairs from University of Virginia.
Mr. Webb is senior vice president of manufacturing with responsibility for overseeing antigen manufacturing and supply activities in support of Novavax’ vaccine candidates. Mr. Webb joined Novavax in May 2014 as senior director of manufacturing, named executive director of manufacturing in December 2016, and then named vice president of manufacturing in December 2018. Prior to joining Novavax, Mr. Webb held numerous operational leadership roles at GlaxoSmithKline and Human Genome Sciences where he had the opportunity to take multiple products from early clinical stage through licensure and launch. He received a bachelor of science degree in biology from Salisbury University and a master of science degree in biotechnology from Johns Hopkins University.
Board of Directors
Dr. Young joined the Novavax board of directors in April 2010 and was appointed chairman in April 2011. He has more than 30 years of experience in the fields of molecular genetics, microbiology, immunology, and pharmaceutical development. Most recently, Dr. Young was MedImmune’s president of research and development, where he had responsibility for regulatory affairs and was instrumental in the development of FluMist® and Synagis®. In 2005, Dr. Young was awarded the Albert B. Sabin Humanitarian Award. Prior to MedImmune, Dr. Young was influential in building the department of molecular genetics at Smith Kline & French Laboratories (now part of GlaxoSmithKline) and culminated as director, department of molecular genetics. Dr. Young was on the faculty of the department of microbiology at Mount Sinai School of Medicine in New York City, New York. He received his bachelor of science degrees in biology and general sciences from Villanova University and a doctorate in microbiology and immunology from Baylor College of Medicine in Houston, Texas.
Chief Executive Officer
Mr. Erck was named president and chief executive officer of Novavax in April 2011. He became a Novavax director in June 2009 and served as its executive chairman of the board beginning in February 2010. From 2000 to 2008, Mr. Erck was president and chief executive officer of IOMAI Corporation, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate. Mr. Erck previously served as president and chief executive officer at Procept, a publicly traded immunology company, as vice president of corporate development at Integrated Genetics (now Genzyme), and in management positions within Baxter International. Mr. Erck currently sits on the board of directors of MaxCyte, Inc. He received an undergraduate degree from the University of Illinois and a master’s degree in business administration from the University of Chicago Booth School of Business.
Dr. Douglas joined the Novavax board of directors in 2010. He has more than 25 years of biotechnology experience having served in corporate development roles at Genzyme Corporation since 1989. Most recently, Dr. Douglas was senior vice president of corporate development and a corporate officer at Genzyme Corporation. As a leader of Genzyme’s corporate development team, Dr. Douglas was involved in numerous acquisitions, licenses, joint ventures, and strategic alliances. From 1982 until its merger with Genzyme Corporation in 1989, Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Dr. Douglas was a postdoctoral fellow in Leroy Hood’s laboratory at the California Institute of Technology. He received a BS in chemistry from the University of Michigan and a PhD from the University of California, Berkeley in biochemistry. He currently serves on the University of Michigan Technology Transfer National Advisory Board.
Mr. Alton joined the Novavax board of directors in 2020. He spent more than 20 years at Gilead Sciences, where he served in an array of leadership roles across a portfolio of responsibilities. From January 2019 until March 2019, Mr. Alton was Gilead’s interim chief executive officer. Prior to that, he was the company’s chief patient officer, responsible for Gilead’s government affairs, public affairs, patient outreach, and engagement initiatives, as well as efforts to facilitate access to its medicines around the world. During his tenure at Gilead, his wide-ranging roles included leadership of commercial operations in Europe, Asia, Latin America, and Africa, as well as government affairs, public affairs, and global medical affairs. He also served as general counsel and chief compliance officer. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP, where he specialized in corporate finance transactions for healthcare and information technology companies. Mr. Alton is a member of the board of directors of Corcept Therapeutics, Enochian Biosciences, and several non-profit organizations, including Black Women’s Health Imperative, AIDSVu, and the Boys and Girls Clubs of Oakland. Mr. Alton received a bachelor’s degree in legal studies from the University of California at Berkeley and a law degree from Stanford University.
Mr. Evans joined the Novavax board of directors in 1998 and served as lead independent director from April 2007 until April 2011 and as chairman from April 2005 until March 2007. He is chairman and chief executive officer at Energy Hunter Resources, Inc. and has been chairman, president, chief executive officer, and founder of GreenHunter Energy, Inc., a NYSE Amex-listed alternative energy company, since 2007. He was chairman of the board of directors and chief executive officer of its predecessor, Hunter Resources, Inc., from 1985 to 1995. Mr. Evans is currently a trustee of TEL Offshore Trust, a NASDAQ-listed oil and gas trust and a board member of Global Hunter Securities, LLC since 2005. Mr. Evans is a serial entrepreneur, having founded, grown, and provided successful exit strategies for several companies, and is highly skilled in capital-raising activities. He was recognized by Ernst & Young as the Southwest Area 2004 Entrepreneur of the Year for the Energy Sector and was recently inducted into the World Hall of Fame for Ernst & Young Entrepreneurs.
Mrs. King joined the Novavax board of directors in 2018. She is the cofounder and chief executive officer of GlycoMimetics, Inc., a clinical-stage biotechnology company. Before founding GlycoMimetics, Inc. in 2003, Mrs. King was an executive in residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. Mrs. King joined NEA after serving as a senior vice president at Novartis Corporation. Before Novartis, Mrs. King spent 10 years with Genetic Therapy, Inc. (GTI), through the company’s early stages, initial public offering, and eventual sale to Novartis, after which she ran GTI as a wholly owned subsidiary of Novartis. Previously, Mrs. King worked at ALZA Corporation and Bain and Company. Mrs. King currently serves on the executive committee of the Biotechnology Innovation Organization (BIO). She also sits on the board of directors of the University of Maryland BioPark. Mrs. King received a bachelors of arts degree from Dartmouth College and a master’s degree in business administration from Harvard Business School.
Mr. McManus joined the Novavax board of directors in 1998. He has served as president, chief executive officer, and director at Misonix, Inc., a medical, scientific, and industrial provider of ultrasonic and air pollution systems, since 1998. Previously, he was president and chief executive officer at New York Bancorp Inc. from 1991 to 1998. From 1990 through November 1991, Mr. McManus was president and chief executive officer at Jamcor Pharmaceuticals Inc. Previously, Mr. McManus served as an assistant to the President of the United States from 1982 to 1985 and held positions with Pfizer Inc. and Revlon Group. Mr. McManus received a BA in economics from the University of Notre Dame and a JD from the Georgetown University Law Center. He served in the US Army Infantry from 1968 through 1970. He is also a recipient of the Ellis Island Medal of Honor.
Dr. Modi joined the Novavax board of directors in April 2009 and represents Satellite Overseas (Holdings) Limited, one of the largest shareholders of Novavax. He has been the managing director at Cadila Pharmaceuticals Ltd., a company organized in India, since 1995, and is director of other Cadila Group companies. Dr. Modi holds a PhD in biological science from the University of Michigan, Ann Arbor, USA. He obtained a MSc in biochemical engineering from Indian Institute of Technology (IIT), Bombay, India. Dr. Modi is the winner of the Genetic Society of America’s Best Scientific Poster at the International Genetics Congress held in August 1988 by the Genetic Society of America. He has presented many papers on various aspects of chemical engineering, biochemical engineering, and biotechnology at many institutes in India and abroad and is a member of many prestigious organizations and associations.
Mr. Mott is currently a private investor through Mott Family Capital. He serves as chairman of the board for Adaptimmune, Ardelyx, Epizyme, Imara, and Mersana. From 2008 to 2020, Mr. Mott was general partner at NEA, one of the world’s largest venture capital firms, which invests in companies across all stages in healthcare and technology. Mr. Mott served as president and chief executive officer, vice chairman of MedImmune from 2000 through 2008, during which he led the sale of the company to AstraZeneca in June 2007 for $15.6 billion. He joined MedImmune in 1992 and served in various senior roles during his tenure, including chief operating officer and chief financial officer. During the course of his career, Mr. Mott has been involved in more than $40 billion in corporate acquisitions, fundraising, partnerships, and other capital formation. He has supported more than 35 initial public offerings or corporate acquisitions, brought in more than a dozen new drugs through development to commercialization, and served on 25 corporate boards. Mr. Mott holds a bachelor of arts degree from Dartmouth College.
Our Partners and
Key Collaborators
Partners energize our mission and expand our reach
Novavax has several active partnerships across the globe. We seek and encourage meaningful partnerships and collaborations with leading biopharma organizations, research institutions, government agencies, and foundations.
Our partners and key collaborators
Coalition for Epidemic Preparedness Innovations (CEPI) has committed to provide Novavax up to $388 million in funding for development and manufacturing of Novavax’ NVX-CoV2373 coronavirus vaccine candidate against SARS-CoV-2.
The mission of CEPI is to stimulate and accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks.
CEPI
CEPI will invest up to $384 million of additional funding, on top of the $4 million it invested in March, to advance the clinical development of NVX-CoV2373, Novavax’ coronavirus vaccine candidate for SARS-CoV-2.
The additional funding from CEPI will also support the rapid scale-up of the NVX-CoV2373 vaccine antigen, as well as the Novavax proprietary Matrix-M™ adjuvant, which is expected to enhance immune responses by stimulating high levels of neutralizing antibodies. In addition, the CEPI funding will allow Novavax to dramatically increase its large-scale manufacturing capacity for both antigen and adjuvant in multiple locations.
The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) is the Joint Service’s lead for development, acquisition, fielding, and life-cycle support of chemical, biological, radiological, and nuclear defense equipment and medical countermeasures.
JPEO-CBRND Enabling Biotechnologies (EB) provides new and improved medical countermeasure responses during a crisis and against future threats.
Novavax has been awarded a contract by the US Department of Defense (DoD) for the manufacturing of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. JPEO-CRBND-EB, through funding provided by the Defense Health Program, has agreed to fund up to $60 million to support Novavax in its production of several components of the vaccine that will be manufactured in the United States. The agreement includes a 2020 delivery of 10 million doses of NVX-CoV2373 for DoD that could be used in Phase 2/3 clinical trials or under an Emergency Use Authorization (EUA) if approved by the US FDA.
Novavax and Serum Institute of India (SII) announced a commercial license agreement for the use of Novavax’ proprietary Matrix-M™ vaccine adjuvant with SII’s malaria vaccine candidate.
Serum Institute of India is the world’s largest vaccine manufacturer based on the number of doses produced and sold globally (more than 1.5 billion doses), which include the polio vaccine as well as the diphtheria, tetanus, pertussis, Hib, BCG, hepatitis B, measles, mumps, and rubella vaccines.
Serum Institute of India
Novavax and Serum Institute of India announced a commercial license agreement for the use of the Novavax proprietary Matrix-M vaccine adjuvant with Serum Institute of India’s malaria vaccine candidate. Serum Institute of India licensed the R21 malaria vaccine, which targets the most severe plasmodium falciparum–induced malaria disease, from the Jenner Institute at Oxford University in 2017. Matrix-M is a key component in the malaria vaccine candidate, currently in a Phase 2b clinical trial sponsored by the Jenner Institute with top-line data expected to be reported in the second quarter of 2020.
In 2009, Novavax formed CPL Biologicals Ltd., a joint venture with Cadila Pharmaceuticals Ltd., to develop a number of Novavax’ VLP vaccine candidates and certain Cadila therapeutic vaccine candidates for territories in India.
Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India. The mission of Cadila Pharmaceuticals is to discover, develop, and successfully market pharmaceutical products to prevent, diagnose, alleviate, and cure diseases.
Cadila Pharmaceuticals Ltd.
In 2009, Novavax formed CPL Biologicals Ltd., a joint venture with Cadila Pharmaceuticals Ltd. to develop a number of Novavax’ VLP vaccine candidates and certain Cadila therapeutic vaccine candidates for territories in India.
Request for proposal
(RFP) overview
Novavax announces projects that are open for competitive bidding.
Novavax is developing NVX-CoV2373, a new vaccine for SARS-CoV-2, in partnership with the Coalition for Epidemic Preparedness Innovations (CEPI). To rapidly advance the program and deliver experimental vaccine doses as soon as possible, Novavax is requesting proposals for multiple projects.
For a list of open requests for proposal or if you would like instructions on how to participate in an RFP issued by Novavax, download our RFP Information Document.
For business development inquiries,
contact busdev@novavax.com